Clinical and Virological Response to Entecavir in HBV-Related Chronic Hepatitis or Cirrhosis: Data from the Clinical Practice in a Single-Centre Cohort

Abstract

Background

Limited data are available on entecavir in Caucasian patients with HBV cirrhosis or chronic hepatitis B who are treated in the clinical practice. The aim was to evaluate the efficacy of entecavir in an Italian cohort of unselected patients with different stages of liver fibrosis, comparing the virological and clinical results obtained between patients with and without liver cirrhosis.

Methods

Efficacy and safety of entecavir were retrospectively evaluated in 100 patients recruited in the Gastro-Hepatology Unit, San Giovanni Battista Hospital (Turin, Italy). A pharmacokinetic analysis was performed in 34 participants to assess whether cirrhosis may affect entecavir metabolism. Participants were followed-up for a median (range) duration of 21 months (2–108).

Results

Rates of virological response (negative viraemia by PCR for ≥2 consecutive determinations) after 12, 24 and 36 months were 91.7%, 97.5% and 93.7%, respectively. In the 84 patients who were treated for ≥12 months, presence of cirrhosis (OR 1.730, 95% CI 1.082, 2.766; P=0.022) and absence of hepatitis B e antigen (OR 0.479, 95% CI 0.273, 0.842; P=0.011) were independent predictors of earlier clearance of serum HBV DNA. There were no differences between the serum concentrations in the steady-state level of entecavir between patients with or without cirrhosis. No significant differences were detected between the average area under the curve in the means of the two groups (P=0.55).

Conclusions

Entecavir represents an excellent therapy in patients with HBV-related liver disease and particularly with cirrhosis where it showed a good profile of tolerability, higher efficacy and an earlier virological response.

References

McMahon

B.J.

Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3–8.

Chen

C.J.

, Yang

H.I.

, Iloeje

U.H.

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49 Suppl 5: S72–S84.

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

Iloeje

U.H.

, Yang

H.I.

, Su

, Jen

C.L.

, You

S.L.

, Chen

C.J.

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315–1341.

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

Carosi

, Rizzetto

, Alberti

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259–265.

Chang

T.T.

, Gish

R.G.

, de Man

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.

10.

Gish

R.G.

, Lok

A.S.

, Chang

T.T.

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437–1444.

11.

Chang

T.T.

, Lai

C.L.

, Kew Yoon

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422–430.

12.

Woo

, Tomlinson

, Nishikawa

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218–1229.

13.

Tenney

D.J.

, Rose

R.E.

, Baldick

C.J.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–1514.

14.

Liaw

Y.F.

, Raptopoulou-Gigi

, Cheinquer

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. Hepatology 2011; 54: 91–100.

15.

Shim

J.H.

, Lee

H.C.

, Kim

K.M.

Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176–182.

16.

Marcellin

, Ziol

, Bedossa

Noninasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242–247.

17.

Fontana

R.J.

Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010; 52: 147–149.

18.

Papatheodoridis

G.V.

, Dimou

, Dimakopoulos

Outcome of hepatitis e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121–129.

19.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–2681.

20.

Lai

C.L.

, Gane

, Chao-Wei

Two-year results from the GLOBE Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine. Hepatology 2006; 44 Suppl 1: 222A.

21.

Zoutendijk

, Reijnders

, Brown

Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443–451.

22.

Buster

E.H.

, Hansen

B.E.

, Buti

Peginterferon α-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388–394.

23.

Schiff

, Simsek

, Lee

W.M.

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776–2783.

24.

Sims

K.A.

, Woodland

A.M.

Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy 2006; 26: 1745–1757.